BCCDC TB registry, we identified all those who met the Public Health Agency of Canada case definition for active TB between January 1, 2003 and December 31, 2012. Within this group, we identified all individuals with laboratory-confirmed HIV infection identified before or 30 days after TB diagnosis. HIVinfected individuals who migrated to BC while on active TB therapy were excluded from analysis. Clinical data were extracted from the BCCDC electronic TB registry and paper charts for all identified HIV-infected TB patients. Population-based estimates of HAART use and HIV prevalence (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) were acquired from the BC Centre for Excellence in HIV/AIDS (BC-CfE), the single provider of free HAART in BC. Description of HIV prevalence estimates in BC have been published elsewhere. 15 The BC-CfE's HAART guidelines have remained consistent with those of the IAS-USA since 1996. 16, 17 Ethical approval for this study was received from the University of British Columbia main campus and St. Paul's Hospital site.
Definitions
TST positivity was defined as a screening TST of 5 mm. High-risk features included the following: foreign birth, a history of TB contact, incarceration, homelessness, illicit drug use or residence in Vancouver's Downtown Eastside (DTES) -an inner city neighbourhood with a high density of socially and economically vulnerable residents. Ongoing high-risk features included homelessness, illicit drug use and living in the DTES. Disease site was classified as pulmonary, extra-pulmonary or both, according to national guidelines. 6 Treatment outcomes were defined as treatment completed, absconded,* death, transfer out, and treatment failure, in accordance with reporting guidelines. 
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Fisher's exact test were used in univariate analysis to test for an association between patient characteristics and treatment outcomes. Polynomial regression was used to examine provincial TB incidence and prevalence of HIV testing over time. Poisson regression was performed to model the association between number of individuals on antiretroviral therapy and the number of TB-HIV cases over time. For regression analysis, we used SAS version 9.3. Statistical significance was set at p=0.05 and all p-values were two-sided. 
RESULTS

Population-level trends in TB incidence
Population-level trends in HIV and HAART usage
From 2003-2012, the estimated number of people with HIV increased from 9,936 to 11,972 in BC ( Figure 1B ). Over the same period, the TB incidence decreased significantly from 1.9 to 0.5 per 1,000 HIV-infected individuals (p<0.001) ( Figure 1C ). This decline occurred at a rate of 13.7% per year, with no statistically significant break-points over this 10-year period. During the same period, effective HAART was expanded throughout the province, with the proportion of prevalent HIV-infected individuals on HAART increasing from 34% to 52% ( Figure 1D ). For each 1% increase in the percentage of individuals on HAART, the estimated number of HIV-infected TB patients decreased by 5% (RR 0.95; 95% CI: 0.93-0.97).
Patient characteristics
A total of 129 HIV-infected TB patients were identified, with a median age of 43 years (IQR 36-49); 94 (73%) were male, 34 (26%) were female and one (1%) was transgender. Most people (72%) were Canadian-born, while 117 (91%) had one or more high-risk features (Table 1) . After excluding a history of previous TB contact and foreign birth, 87 (67%) had ongoing high-risk features. There were 90 people (70%) with a CD4 count available at diagnosis; median CD4 count was 130/mm 3 (IQR 60-240). The median viral load available from 36 individuals (28%) at diagnosis was 32,391 copies/mL (IQR 17,000-100,000); 52 people (40%) were known to be taking HAART at the time of TB diagnosis. In terms of clinical presentation, 80 people (62%) were classified as pulmonary, 23 (18%) were extra-pulmonary, and 25 (19%) had both extrapulmonary and pulmonary manifestations. Meningitis was diagnosed in 14 individuals (11%).
TB screening and preventive therapy
In total, 22 people (17%) were diagnosed with HIV concurrent with or subsequent to their TB diagnosis and 2 (2%) were previously treated for TB and had relapsed disease. After excluding these 24 people, 105 HIV-infected individuals were considered eligible for TST screening prior to their TB diagnosis ( Figure 2 ). Of the 105, only 64 (61%) had a documented TST, and of those, 39 (37%) were TST positive. Of the 39 TST-positive individuals, 30 (77%) did not receive LTBI therapy and 8 (21%) did not complete LTBI therapy. Of 25 people with prior negative TST, 21 (84%) were not tested in the 12 months preceding their TB diagnosis, and 14 (56%) had at least one ongoing high-risk feature. Of the remaining 41 people without a screening TST, 29 (71%) had no prior testing known and 7 (17%) had a documented TST placement but no TST result recorded. Two 
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individuals (5%) were diagnosed with TB on chest x-ray imaging as part of immigration screening and three (7%) had insufficient information on whether or not they had TST screening.
Treatment outcomes
After the exclusion of people with ongoing active TB therapy and those transferred out of province, there were 121 with data available to evaluate outcomes; 76 (63%) achieved treatment completion, 32 (26%) died, 3 (2%) relapsed, and 10 (8%) absconded (Table 1) . On univariate analysis, only HAART use at diagnosis was associated with successful outcomes (P=0.031). Of note, only 15 people completed TB treatment under directly observed therapy. There were 16 individuals with drug-resistant strains, including 7 with rifampin monoresistance. Active TB was the specific cause of death in 6 people and contributed to death in 14. There was an association between HAART use at diagnosis and successful treatment outcome (p<0.001).
DISCUSSION
This population-based study demonstrated an association between HAART scale-up and a decline in TB incidence in the HIV-infected population of BC. Although other social and medical factors likely contributed to the reduction in TB incidence in the HIV-infected population, this association cannot be ignored. Over 10 years, the number of HIV-infected TB patients has declined nearly fourfold in the province of BC. Although this is certainly a positive trend, the fact remains that the incidence of TB in the HIV-infected population is approximately 10 times the Canadian average. 6 Moreover, TB continues to affect the most socially vulnerable populations with devastating consequences; over one quarter of HIV-infected TB patients died while on anti-TB medications and less than two thirds of patients successfully completed therapy.
In our study population, the majority of patients did not have TST screening results recorded. In those with positive screening TSTs, over 90% did not start or complete LTBI therapy. This highlights the need to focus our attention on implementation strategies for TB screening in HIV-infected populations. TB programs do not suffer from ineffective tests or TB treatment; a positive TST is highly predictive for TB in HIV-infected populations and LTBI therapy is highly effective in HIV-infected populations in low-incidence regions. Indeed, a recent study in Switzerland estimated that treating 15 HIV-infected TST-positive individuals with LTBI therapy would prevent one new case of TB-HIV. 19 Instead, the problem with TB prevention in HIV-infected populations appears to be related to implementation. Screening uptake and LTBI treatment completion both appear to be suboptimal in real world conditions, despite the high risk of TB in HIV-infected individuals. 9, 10 Interferon gamma release assays (IGRAs) could potentially be used to improve screening uptake, as IGRAs can be drawn with other routine bloodwork after HIV diagnosis, and they do not require a 48-72 hour return visit for reading. 6 However, IGRAs present their own challenges, including a lack of long-term followup data in HIV-infected populations, and high rates of conversion and reversion on serial testing. 20 In addition, we noted that only seven patients failed to return for TST reading in this study, indicating that the return for reading may not be a significant barrier to the effectiveness of TST screening.
Data from numerous cohort studies and randomized control trials have demonstrated that HAART is effective in reducing TB risk in HIV-infected individuals. [21] [22] [23] [24] [25] [26] [27] [28] [29] On a population level, however, the exact contribution of HAART to the reduction in TB incidence in HIV-infected population is less well characterized. 5, 13 We could expect that contact structure may influence TB incidence at a population level, particularly if marginalized or populations at high risk for TB are targeted for HAART. Population-based data are beginning to emerge from low-incidence regions. Studies from California (1993 California ( -2008 and the United Kingdom (2002-2010) demonstrated a 71% reduction in TB incidence in HIV-infected populations. 5, 13 We note a similar reduction in our populationbased study.
The association between HAART use at diagnosis and successful treatment outcome is also noteworthy, but is likely confounded by several factors, including access to health care, medication adherence, psychiatric co-morbidity, socio-economic status and delay in diagnosis. This association between HAART and improved outcomes does underline the need for early diagnosis and treatment of HIV.
This study has several strengths. First, the comprehensive data capture at the population level for both HIV and TB allows us to determine a valid estimate of TB incidence in the HIV-infected population of our province. Centralized reporting and recording of LTBI test results also allows us to understand the uptake of screening procedures prior to active TB diagnosis in this population while centralized HAART recording allows for accurate estimation of HAART uptake over time.
There are several limitations to this study. TST screening results may be incomplete, as some practitioners who treat HIV-infected patients may not uniformly report TST negative results to the BCCDC. We believe, however, that our comprehensive review of referral letters, patient narratives, and public health records was unlikely to miss a significant proportion of TB screening tests. Furthermore, the number of TST-positive individuals who were untreated or inadequately treated is larger by far than the number of treated individuals. This is consistent with the notion that on a population level, a positive TST is predictive of TB in people infected with HIV, and that LTBI therapy is likely protective in a low-incidence setting. Second, there is incomplete HIV screening data in TB patients over this period. Given the increased proportion of people screened for HIV over the decade, we feel it is unlikely that missed cases of HIV are responsible for the reduction in TB-HIV incidence.
We must consider the possibility that the association between HAART scale-up and reduction in TB incidence was confounded by other factors, including an overall decrease in provincial TB incidence, improved access to health care in HIV-infected populations, improved housing in high-risk communities, and a decrease in HIV incidence over the decade. Given the known association between the scale-up of HAART use and the dramatic reduction in TB incidence, however, we believe that HAART is at least partially responsible for this reduction in HIV-TB incidence.
In conclusion, the incidence of TB in the HIV-infected population of BC decreased significantly over the past decade despite suboptimal TB prevention practices. This is most likely attributable to the increased effectiveness of HAART. HIV-TB coinfection remains an important issue in BC, affecting vulnerable populations with high rates of substance abuse and co-morbidities. Our results suggest that further scale-up of HIV testing, and HAART e262 REVUE CANADIENNE DE SANTÉ PUBLIQUE • VOL. 105, NO. 4
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coverage, coupled with comprehensive TB screening and LTBI treatment, can lead to TB-HIV elimination in BC and in other lowincidence regions.
RÉSUMÉ
OBJECTIF : Avant l'avènement de la thérapie antirétrovirale hautement active (TAHA), la tuberculose progressive était l'un des principaux facteurs de morbidité et de mortalité liées au VIH au Canada et dans d'autres régions à faible incidence. Notre étude visait à examiner l'incidence de la tuberculose, ses manifestations cliniques et le recours au dépistage chez les patients tuberculeux infectés par le VIH à l'ère de la TAHA.
MÉTHODE :
Nous avons mené une étude rétrospective de tous les patients tuberculeux infectés par le VIH en Colombie-Britannique sur une période de 10 ans (2003-2012) . Nous avons extrait leurs caractéristiques démographiques et cliniques, ainsi que les données sur le dépistage et les effets du traitement. Nous avons aussi examiné les tendances de l'incidence de la tuberculose, du dépistage du VIH et de la prévalence de la TAHA dans la province.
RÉSULTATS :
En tout, 2 839 cas de tuberculose ont été signalés en C.-B. au cours de la période, dont 129 patients tuberculeux infectés par le VIH. Étonnamment, seuls 64 patients tuberculeux infectés par le VIH (50 %) avaient subi un test cutané à la tuberculine (TCT) consigné en dossier avant leur diagnostic de tuberculose. Sur les 39 patients tuberculeux infectés par le VIH ayant eu un TCT positif au préalable, 38 (97,4 %) n'avaient pas suivi un traitement préventif complet à l'isoniazide. L'incidence de la tuberculose a considérablement diminué dans la population infectée par le VIH en C.-B. au cours de la période de l'étude, passant de 1,9 à 0,5 cas de tuberculose pour 1 000 personnes infectées par le VIH (p<0,001).
CONCLUSION : L'incidence de la comorbidité VIH-tuberculose a considérablement diminué au cours de la dernière décennie malgré les pratiques sous-optimales de prévention et de dépistage de la tuberculose latente. Cette incidence réduite de la tuberculose est probablement imputable au recours accru à la TAHA. Il faudrait envisager d'intensifier les efforts de prévention afin d'accélérer l'élimination de la tuberculose au sein des populations infectées par le VIH dans les régions à faible incidence.
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